Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

• Published in: Bone marrow transplantation (Basingstoke) Vol. 57; no. 5; pp. 753 - 759
• Main Authors: Lindahl, Hannes, Vonlanthen, Sofie, Valentini, Davide, Björklund, Andreas T., Sundin, Mikael, Mielke, Stephan, Hauzenberger, Dan
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 2022; Nature Publishing Group
• Subjects: 45/23; 45/77; 631/250/1854/2812; 692/499; 692/699/1541/1990/283/1897; 692/700/1750; Acute myeloid leukemia; Bone marrow; Cell Biology; Chimerism; Deoxyribonucleic acid; DNA; Graft rejection; Hematology; Hematopoietic stem cells; Internal Medicine; Leukemia; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Public Health; Rank tests; Risk; Stem cell transplantation; Stem Cells; Transplantation
• ISSN: 0268-3369; 1476-5365; 1476-5365
• DOI: 10.1038/s41409-022-01615-8

Recipient–donor chimerism is routinely analyzed after allogeneic hematopoietic stem cell transplantation (HSCT) to monitor engraftment and graft rejection. For malignancies, chimerism can also be used to screen for disease relapse post-HSCT but methodology and interpretation of results are not standardized and likely depend on underlying diagnosis. We have implemented highly sensitive and accurate methodologies for chimerism analysis for the purpose of improving relapse prediction. Here, we report an exploratory retrospective analysis of clinical routine chimerism results from all 154 HSCTs for acute myeloid leukemia (AML) performed at our center during the years 2015–2020 with the aim of suggesting a clinically useful threshold at which risk of relapse is high. Relapse was not reliably predicted based on single elevated chimerism values obtained before time of overt relapse. However, early complete donor chimerism, here defined as recipient DNA < 0.2% in CD33 + cells in any blood or bone marrow sample taken during the first 60 days after HSCT, correlated inversely with relapse during the observation time (log-rank test P  = 0.033). We propose that achievement of complete chimerism determined early after HSCT using sensitive methods can be used for risk-stratification of AML patients.